Skip to main content

Table 1 Patient characteristics

From: EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus

 

Female, N (%)

Male, N (%)

All, N (%)

Number of patients

79 (35.9)

141 (64.1)

220

Age at diagnosis (years)

 Median

77

72

74

 Range

33–93

43–90

33–93

Site of primary tumour

 Distal oesophagus

4 (5.1)

16 (11.3)

20 (9.1)

 GOJ/cardia

17 (21.5)

46 (32.6)

63 (28.6)

 Corpus

21 (26.6)

44 (31.2)

65 (29.5)

 Antrum/pylorus

37 (46.8)

35 (24.8)

72 (32.7)

Tumour differentiation grade

 Grade 1

14 (17.7)

16 (11.3)

30 (13.6)

 Grade 2

33 (41.8)

70 (49.6)

103 (46.8)

 Grade 3

32 (40.5)

55 (39.0)

87 (39.5)

Stage at diagnosis

 IA

15 (19.0)

18 (12.8)

33 (15.0)

 IB

7 (8.9)

19 (13.5)

26 (11.8)

 IIA

17 (21.5)

33 (23.4)

50 (22.7)

 IIB

14 (17.7)

19 (13.5)

33 (15.0)

 IIIA

7 (8.9)

21 (14.9)

28 (12.7)

 IIIB

11 (13.9)

19 (13.5)

30 (13.6)

 IIIC

1 (1.3)

5 (3.5)

6 (2.7)

 IV

7 (8.9)

7 (5.0)

14 (6.4)

Residual tumour classification

 R0 (no residual tumour)

62 (78.5)

105 (74.5)

167 (75.9)

 R1 (microscopic residual tumour)

5 (6.3)

19 (13.5)

24 (10.9)

 R2 (macroscopic residual tumour)

8 (10.1)

9 (6.4)

17 (7.7)

 Rx (unknown)

4 (5.1)

8 (5.7)

12 (5.5)

Perioperative and adjuvant therapya (N = 206)

 Only chemotherapy

7 (9.7)

24 (17.9)

31 (15.0)

 Chemoradiotherapy

4 (5.6)

16 (11.9)

20 (9.7)

 Only radiation therapy

1 (1.4)

4 (3.0)

5 (2.4)

 No adjuvant therapy

58 (80.6)

89 (66.4)

147 (71.4)

 Unknown

2 (2.8)

1 (0.7)

3 (1.5)

Tumour recurrenceb(N = 195)

 No recurrence

55 (79.7)

82 (65.1)

137 (70.3)

 Single metastasis >6 months

10 (14.5)

26 (20.6)

36 (18.5)

 Multiple metastases >6 months

4 (5.8)

18 (14.3)

22 (11.3)

Follow-up status

 Alive and free of disease

22 (27.8)

31 (22.0)

53 (24.1)

 Alive with disease

1 (1.3)

1 (0.7)

2 (0.9)

 Died of disease

43 (54.4)

74 (52.5)

117 (53.2)

 Died of other cause

12 (15.2)

30 (21.3)

42 (19.1)

 Unknown cause of death

1 (1.3)

5 (3.5)

6 (2.7)

  1. GOJ gastro-oesophageal junction
  2. aExcluding stage IV, bExcluding stage IV and recurrence <6 months